Suzhou Industrial Park Bioventure Investment Management Limited (Bioventure) was established in September 2013. Bioventure its first element of the new bio-industry funds 540 million yuan fund size. Bioventure specialize in the field of life sciences in the early stages of the venture capital investments as having high strength and growth, greater development space, excellent management team, biotechnology, drug discovery, medical devices and healthcare services companies, and provide capital, management , operation and other aspects of post-investment support and services. Bioventure brought together senior investment professionals team with bio-pharmaceutical industry investment experience, strong fund management, entrepreneurship and venture capital and operating experience in business, have a deep understanding of the domestic and foreign markets, capable of its forward-looking international perspective and extensive The industry has the potential resources to help innovative companies grow rapidly and gain greater success, while giving fund investors bring considerable returns. Suzhou Industrial Park, the core investor BioBay has the country's best medical and pharmaceutical incubator function, use the platform, the project team has great resources and industrial service advantages, Yuan-sheng venture has successfully invested in 20 projects have been cast projects in their own development and follow-up financing, has made outstanding achievements in the industry for all to see, and won the Venture's trust and praise. By focusing and extensive industry resources, Bioventure determined to become one of China's most successful medical and pharmaceutical venture fund. Bioventure expectations and in the medical and pharmaceutical industry where there joint venture development cooperation.
RootPath Genomics, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2017. It specializes in developing a personalized T-cell therapy platform that integrates precision medicine with cancer immunotherapy. The company's innovative technologies focus on the analysis and manipulation of individual immune cells, enabling advancements in immune and cell therapy. By precisely monitoring and modulating the immune system, RootPath aims to enhance the diagnosis and treatment of cancer, contributing to significant improvements in patient outcomes.
Shanhai Innovation
Series C in 2025
Shanhai Innovation is a biological development company focused on supramolecular science and technology research and development. It provides supramolecular material, organic liquid, ionic salt, and biocatalysis. It serves biomedicine, daily cosmetics, health food, medical equipment, and food additives.
Hengyu Medical
Venture Round in 2025
Hengyu Medical is a medical device firm focused on R&D and production of IVUS and optical coherence tomography, and catheter equipment.
Degron Therapeutics
Series A in 2025
Degron Therapeutics is a drug discovery platform focused on developing a new class of targeted protein degradation therapeutics, specifically small molecule molecular glue degrader drugs. The company aims to become a leader in the discovery and development of these innovative medicines, which target disease mechanisms that are often inaccessible to traditional small molecule inhibitors. By leveraging its advanced molecular glue protein degradation platform technology, Degron Therapeutics identifies and validates disease targets while creating novel selective compounds. This approach addresses significant unmet medical needs across various therapeutic areas. The company boasts a team of experienced executives and scientific leaders dedicated to enhancing treatment efficiency through its drug development initiatives.
MyoGene Life Sciences
Series A in 2025
MyoGene Life Sciences is a regenerative medical company that specializes in the promotion of its regenerative repair material product line for bone repair.
AusperBio
Series B in 2024
AusperBio is a clinical-stage biopharmaceutical company focused on developing innovative treatments for hepatitis B and advancing oligonucleotide therapeutics. Utilizing its proprietary Med-Oligo™ ASO platform, the company aims to enhance targeted delivery technologies to improve treatment outcomes. AusperBio is dedicated to addressing a variety of diseases, including viral infections, genetic disorders, metabolic conditions, and immune diseases, through its small interfering ribonucleic acid (siRNA) drugs. By concentrating on effective treatment strategies and vaccination for chronic hepatitis B, AusperBio seeks to provide patients with improved therapeutic options and protection against this challenging disease.
Yili Pharmaceutical
Seed Round in 2024
Yili Pharmaceutical is a pharmaceutical R&D company that mainly engages in biochemical product technology R&D, medical research and experimental development, engineering and technology research and experimental development, and software development.
Allink Biotherapeutics
Series A in 2024
Allink Biotherapeutics is a biopharmaceutical company that focuses on oncology and immunological treatment.
MacroLux
Series B in 2024
MacroLux is a medical technology company that specializes in endoscopic interventional solutions for diagnosis and treatment. The company focuses on developing devices that enhance the detection and treatment of conditions in urology, respiratory, and digestive health. By offering advanced endoscopic therapies, MacroLux aims to improve patient outcomes through earlier diagnosis and more effective treatment options, catering to a wide range of medical customers.
Youzhong New Material Technology
Series A in 2024
Youzhong New Materials is a micro-nano device R&D company that designs, develops, and manufactures micro-nano devices using nanoimprint core technology.
Chuanxin Biotech
Venture Round in 2024
Chuanxin Biotech is an RNA drug research and development service provider.
Changsha Morning Shine
Series A in 2023
Changsha Morning Shine is an innovative pharmaceutical company that specializes in R&D outsourcing, biomedicine, chemical drugs, and biotechnology services.
Shenzhen CardioACC
Seed Round in 2023
Shenzhen CardioACC Ltd specializes in advanced cardiovascular interventional, natural cavity imaging and advanced diagnostic procedures.
KeChow Pharma
Funding Round in 2023
KeChow Pharma, Inc. is a biopharmaceutical company focused on novel drug discovery.
Gachun Biotech
Series A in 2023
Gachun Biotech is a pharmaceutical intermediates industrialization platform that focuses on APIs, or pharmaceutical intermediates.
Huili Pharmaceutical
Series A in 2023
Huili Pharmaceutical is a drug delivery platform that specializes in the development of nanoparticles and microsphere preparation equipment.
Shennapsi Artificial Intelligence Technology
Series A in 2023
Synapsor is a medical-grade wearable device research and development company, oriented to the AI+ medical and health field, and is committed to the development and manufacturing of AI-powered medical-grade smart wearable devices, including AI-ECG artificial intelligence. Diagnostic analysis system, CUMS uric acid blood glucose and cholesterol monitoring system, etc. The company has recently received tens of millions of yuan in Series B investment, and the investor is Xiaomi Technology.
Essentia Biosciences
Angel Round in 2023
Essentia Biosciences is a biotechnology company that specializes in the development of cells, gene technology drugs, and medical devices.
Jiamuyao Medical
Seed Round in 2023
Jiamuyao Medical specialized in developing an energy platform for the comprehensive treatment of complex intravascular lesions.
Xiguang Bio
Series B in 2023
Xiguang Bio focuses on the production of diagnostic reagents and provides chemiluminescent raw materials and overall system technology solutions.
Panomic Biomedical Technology
Series A in 2023
Suzhou Panomic Biomedical Technology Co., Ltd. (BioNovoGene) was founded in Suzhou Industrial Park Bio-Nano Park in 2013. It is a leading high-tech enterprise focusing on metabolomics in China. Since its establishment, it has established a complete metabolomics detection and analysis platform - PanomicTM / Bionovogene, including metabolite preprocessing platform, high-resolution mass spectrometry analysis platform, and metabolomics data analysis with independent intellectual property rights The system has perfect biomarker discovery capabilities and clinical application capabilities. The company's scientific research team has a rich background, covering biochemistry, bioinformatics, epidemiology and biostatistics, computer science, etc., and has a consultant team composed of top scientists and clinicians.
Chromai
Venture Round in 2023
Chromai specializes in high-performance intelligent liquid chromatography and medical diagnostic solutions, focusing on simplifying the diagnostic and testing processes. The company employs advanced technologies such as artificial intelligence, Big Data, and the Internet of Things, integrating these with leading analysis and detection methods. Chromai is dedicated to enhancing the fields of health in vitro diagnostics, environmental protection, and scientific instruments. Committed to independent innovation, the company aims to contribute to the revitalization of national industry while providing efficient diagnostic and testing analysis for medical users.
Ruoyi Biotech
Seed Round in 2023
Ruoyi Biotech is a developer of macromolecular drug delivery technology.
Innovision
Series A in 2023
Innovision is a developer of auxiliary diagnosis and treatment systems. It serves the clinical needs of endoscopy centers in various hospitals, uses artificial intelligence technology to process digestive endoscopy image data, shares the workload of endoscopy doctors, and reduces the number of endoscopy doctors.
Chime Biologics
Series B in 2023
Chime Biologics, is a world-class experienced Contract Development and Manufacturing Organization (CDMO), providing customer-centric and cost-effective services for timely premier-quality biopharmaceutical development and manufacturing. We provide a comprehensive solution supporting our customers from analytical and process transfer to early-stage biopharmaceutical development through late-stage clinical and commercial drug substance and drug product manufacturing for Global Supply.
Power Site
Series B in 2023
Power Site is a modern technology enterprise that supplies X-ray imaging core components. It mainly provides high-voltage generators (HVG), combined X-ray sources, power distribution units (PDU), and other core components overall solutions for X-ray imaging systems. The products are mainly used in high-end X-ray imaging systems such as CT, DR, mammography, C-arm, CBCT, security inspection, industrial inspection, etc. The company has an advanced and efficient manufacturing platform with an annual production capacity of 50,000 units.
Yike Polymers
Series B in 2023
Eco Polymer specializes in designing and manufacturing plastic tubes and parts. They provide products for polyethylene, polypropylene, polyamine, elastomers, fluoropolymers, and other various polymers. They serve the medical instrument, auto, electronics, fiber optics, semiconductor, chemical engineering, environment, and analytics industries.
Human Zhizao
Series A in 2023
Human Zhizao is a technology platform that provides comprehensive diagnostic solutions. They provide clinical customers with a parallel, full-automatic multiple flow cytometry fluorescence detection platform and supporting reagents. They provide customer service. The flow fluorescence luminescence technology is a new generation of throughput detection and analysis platform integrating flow analysis, laser analysis, digital signal processing, and other technologies. They involve projects that require the joint detection of multiple indicators, such as autoantibodies, allergens, cytokines, etc.
Lealing Biotech
Venture Round in 2023
Lealing Biotech developes anti-body based drugs and pharmaceutical products.
ProxyBio
Venture Round in 2023
ProxyBio develops treatment and pharmaceutical products for mRNA development.
Hanchao Pharmaceuticals
Venture Round in 2023
Hanchao Pharmaceuticals is a biopharmaceutical manufacturer that develops medicines and other medical equipment.
Yangqi Intelligent
Angel Round in 2022
Yangqi Intelligent provides answers for medical equipment. It provides goods like qise, elixir, wonder vision, odd control, and more. A self-made radiation body surface monitoring camera is called wonder vision. Qice is a platform for artificial intelligence-based medical models. Sales.
Pulnovo Medical
Venture Round in 2022
Pulnovo Medical, founded in 2013 in Wuxi, Anhui, specializes in the development, production, and service of innovative medical devices aimed at treating pulmonary hypertension. The company focuses on advanced pulse radiofrequency ablation technology, which includes pioneering high-frequency ablation equipment and intravascular catheters. These products are designed to enhance the quality of life for patients suffering from pulmonary hypertension and heart failure, offering a novel approach to treatment with a commitment to improving patient outcomes. Pulnovo Medical holds global invention patents for its unique technologies, underscoring its role as a leader in this specialized medical field.
Cell Probio
Series B in 2022
Cell Probio is a manufacturer of cell culture consumables, positioned in the R&D, production and sales of high-end biological consumables.
Palline
Series A in 2022
Palline is a company that specializes in hospital management solutions and operational data analysis. It leverages data to encourage hospital management to implement lean practices and enhance the allocation of medical resources through strategic adjustments. By employing statistical methods and artificial intelligence, Palline develops mathematical models for performance evaluation and incentive system construction. This enables hospital operators to conduct strategy analysis and quantitative evaluations more efficiently. The company offers comprehensive solutions that encompass management concepts, tools, big data applications, and software systems, all aimed at optimizing hospital operations and resource allocation.
Zhongguancun Shuimu Medical Technology
Series A in 2022
Zhongguancun Shuimu Medical Technology is the operator of a third-party, competent medical device compliance organization. Their business helps companies cut costs and time to market by offering medical device compliance services. It is dedicated to accelerating the registration and listing procedures for new medical device items as well as addressing the issue of how to industrialize creative medical device firms.
JoyMed Technology
Series B in 2022
JoyMed Technology specializes in the research and development, registration, and manufacturing of medical devices, offering comprehensive solutions to medical equipment manufacturers. The company focuses on creating innovative and reliable technologies while ensuring high-quality product standards. By providing services such as device design, risk management, marketing, and product verification and validation, JoyMed Technology helps clients streamline their processes and reduce time to market. The firm aims to be a trusted partner for both domestic and international medical device companies, particularly assisting small and medium-sized enterprises in navigating the complexities of the medical product market. Through a flexible cooperation model and experienced team design, JoyMed Technology seeks to foster mutual growth with its customers.
Future Vision
Series B in 2022
Future Vision provides myopia prevention and control, amblyopia rehabilitation training, and medical optometry for children aged 3-16
Ehomepoct
Series C in 2022
Ehomepoct is a healthcare management company based in Changsha, China, specializing in the manufacture of diagnostic test kits. The company produces a range of products, including pregnancy tests, inflammation tests, and menstrual period tests, as well as early embryo testing. Ehomepoct also focuses on integrating artificial intelligence into medical treatment applications, enhancing rapid diagnosis and health management services.
Degron Therapeutics
Series A in 2022
Degron Therapeutics is a drug discovery platform focused on developing a new class of targeted protein degradation therapeutics, specifically small molecule molecular glue degrader drugs. The company aims to become a leader in the discovery and development of these innovative medicines, which target disease mechanisms that are often inaccessible to traditional small molecule inhibitors. By leveraging its advanced molecular glue protein degradation platform technology, Degron Therapeutics identifies and validates disease targets while creating novel selective compounds. This approach addresses significant unmet medical needs across various therapeutic areas. The company boasts a team of experienced executives and scientific leaders dedicated to enhancing treatment efficiency through its drug development initiatives.
SiranBio
Angel Round in 2022
SiranBio is a biotechnology that develops innovative siRNA drugs.
Resproly
Series B in 2022
Resproly is a company engaged in the research, development, production, and sales of formulations and equipment for respiratory inhalation. It operates as an integrated enterprise, concentrating on multiple clinically significant treatment areas, including asthma, chronic obstructive pulmonary disease (COPD), diabetes, and Parkinson's disease. By focusing on inhaled formulations and advanced pulmonary drug delivery technology, Resproly aims to address the therapeutic needs associated with these conditions, contributing to improved patient outcomes in respiratory health.
NeuroEchos
Series A in 2022
NeuroEchos, established in August 2017, specializes in functional neurosurgery by offering integrated diagnosis and treatment solutions for conditions linked to abnormal nervous system activity. The company utilizes advanced artificial intelligence to assist in diagnosing and interpreting electroencephalogram (EEG) waves, enhancing the accuracy of neurological assessments. Additionally, NeuroEchos supports neuroscience research through the development and provision of deep brain electrodes, contributing to a better understanding of neurological disorders and improving patient outcomes.
Baikuirui
Seed Round in 2022
Biocreatech is a biotechnology firm that uses protein design and synthetic biology to create cell factories capable of producing a range of products such as drug intermediates, fine chemicals, functional peptides, and therapeutic proteins. They involve in integrating multiple proteins into molecular machines in order to transform cells into factories.
Enzymaster
Series C in 2022
Enzymaster (Ningbo) Bio-Engineering Co., Ltd. specializes in the development and commercialization of innovative enzyme technologies and biocatalytic synthesis for various industries, including pharmaceuticals, food, and environmental applications. Founded in 2013 and based in Ningbo, China, the company produces a range of products, such as L-tert-leucine and D-Calcium Pantothenate, aimed at enhancing the production of active pharmaceutical ingredients, fine chemicals, and consumer goods. Enzymaster is committed to sustainable practices and focuses on environmentally friendly manufacturing through enzyme-directed evolution and strain engineering. By advancing these technologies, the company seeks to improve both societal and environmental outcomes while promoting safer manufacturing processes.
Junsai Shengwu
Series A in 2022
Junsai Shengwu developes therapies for new solid tumor cell.
Juncell Therapeutics
Series A in 2022
Juncell Therapeutics focuses on developing innovative therapies and pharmaceutical drugs specifically for tumor treatment. The company specializes in tumor cell therapy, offering solutions to isolate tumor-infiltrating lymphocytes (TILs) from tumor tissues. These TILs are subsequently developed outside the human body and re-injected into patients, allowing for targeted treatment of tumors. This approach aims to enhance the effectiveness of cancer therapies while minimizing side effects, ultimately improving patient outcomes in the fight against cancer.
Shengshi Technology
Seed Round in 2022
Shengshi Technology is a specialized platform focused on experimental simulation using computational fluid dynamics (CFD) and artificial intelligence for medical engineering research, particularly related to cardiovascular diseases. The company develops non-invasive precision diagnostic and treatment solutions, leveraging advanced technologies such as external fluid dynamics experimental simulation and CFD numerical simulation. By integrating these key technologies, Shengshi Technology aims to enhance the quality of healthcare services for both doctors and patients, ultimately improving outcomes in the management of cardiovascular conditions.
InnoBM Pharmaceuticals
Venture Round in 2022
InnoBM Pharmaceuticals is engaged in the manufacturing of biomaterials and pharmaceutical products. The company focuses on developing novel therapeutics aimed at enhancing the efficacy of tumor immunotherapy. By prioritizing innovation, InnoBM Pharmaceuticals is dedicated to delivering advanced treatment options for cancer patients, thereby contributing to the improvement of cancer care and patient outcomes.
Guangwei Pharmaceuticals
Venture Round in 2022
Guangwei Pharmaceuticals is a pharmaceutical manufacturer in China that produce medical theater products.
Yuanjingtaico
Seed Round in 2021
Yuanjingtaico is a biotech firm focused on the R&D of fluorescent PCR reagents, microfluidic, and electrochemical detection products.
Lingtai Biotechnology
Seed Round in 2021
Lingtai Biotechnology is a pharmaceutical and biotechnology based company that develops targeted protein degradation drugs.
Changmugu Medical
Series B in 2021
Beijing Changmugu Medical Technology Co., Ltd. is a healthcare startup specializing in artificial intelligence-powered solutions for orthopedic surgery. The company focuses on enhancing the accuracy and safety of surgical procedures through advanced technologies, including AI-assisted diagnosis and individualized operation plans. Additionally, it offers 3D printing patient-specific instrumentation (PSI) for surgical navigation and post-operative intelligent evaluation services. By leveraging AI deep learning, Changmugu Medical aims to provide innovative tools that improve patient outcomes and streamline surgical processes, ultimately contributing to safer and more stable operations in the field of orthopedics.
Comma Bio
Series A in 2021
Comma Bio is a comprehensive solution provider for sample pretreatment. Based on two types of snap-neck material technologies of adsorption and separation materials and filter materials, the company has created three major technology platforms for porous plastics, separation materials and precision injection molding. Customers in the fields of, precision medicine, analysis and testing provide comprehensive solutions for sample pre-processing.
Tripod Preclinical Research
Venture Round in 2021
Tripod is a Contract Research Organization in the biopharmaceutical space that provides preclinical research services for global pharma companies, R&D enterprises and institutes, and medical device developers. Tripod (TPR) is dedicated to nonclinical research (drug safety evaluation) for the candidates of new chemical entity (NCE), food additives, biologics,pesticides,veterinary drugs, and new cosmetics.
Hopstem
Series B in 2021
Hopstem Biotechnology LLC is a Houston-based company that focuses on the development of neural stem cell technology and stem cell therapies specifically for neurological disorders. Established in 2019, the company specializes in the neural differentiation, cell banking, and cell engineering of human induced pluripotent stem cells (iPSCs) and human embryonic stem cells (ESCs). By leveraging its advanced technologies, Hopstem aims to enhance biomedical research and improve diagnostic and therapeutic options for various neurological conditions. Through its innovative approaches, the company seeks to provide effective treatment solutions for patients suffering from these disorders.
BiOligo
Series A in 2021
Shanghai Bailige Biotechnology Co., Ltd. integrates professional management, R&D, production, and service teams.Bioligo establishes and provides high-quality DNA synthesis/sequencing, experiments, production, and various customized services.
Guangzhou Creative Biosciences
Series D in 2021
Creative Biosciences is a biomedical technology company focused on developing and producing diagnostic products for tumor screening, particularly in the realm of colorectal cancer. The company specializes in fecal DNA detection technology, providing non-invasive screening kits that allow medical practitioners to accurately identify genetic abnormalities in fecal samples. These diagnostic tools are designed to aid in the early detection of intestinal cancer lesions, thereby supporting healthcare professionals and researchers in their efforts to improve cancer treatment outcomes. Through its innovative approach, Creative Biosciences aims to enhance cancer screening processes and contribute to better patient care.
Boan Biotech
Series B in 2021
Boan Biotech is a fully integrated biopharmaceutical company specializing in the development, manufacture, and commercialization of therapeutic antibodies. The company focuses on several key therapeutic areas, including oncology, metabolism, autoimmunity, and ophthalmology. While it primarily generates revenue from customers in Mainland China, Boan Biotech aims to expand its reach globally. The company is committed to delivering high-quality biologics to address unmet medical needs in these critical fields.
Vision X
Series B in 2021
Vision X is a solutions provider for medical equipment in the field of ophthalmology and optometry.
Reforgene Medicine
Series A in 2021
Reforgene Medicine is a biomedical company focused on developing innovative drugs aimed at curing genetic diseases, chronic diseases, and cancer. Utilizing advanced gene editing and genomic technologies, the company works on creating programmable medicine that enhances treatment options for patients. By leveraging these cutting-edge techniques, Reforgene Medicine strives to improve patient outcomes and provide effective solutions for complex health challenges.
Alebund Pharmaceuticals
Series B in 2021
Alebund Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapies for renal diseases and related chronic conditions. The company specializes in the research, development, regulatory approval, and commercialization of medicines aimed at treating various kidney diseases, including chronic kidney disease, complications associated with dialysis, nephropathy, diabetic kidney disease, and autosomal dominant polycystic kidney disease. With a diversified and balanced pipeline of drug candidates, Alebund Pharmaceuticals aims to provide comprehensive and high-quality solutions for patients suffering from renal diseases.
NeuExcell Therapeutics
Seed Round in 2021
NeuExcell Therapeutics is an early-stage gene therapy company dedicated to addressing neurodegenerative diseases and neural injuries. The company has developed a novel neural repair technology that employs in vivo astrocyte-to-neuron conversion. By introducing neural transcription factors through adeno-associated virus-based gene therapy, NeuExcell aims to restore damaged neural tissue. This innovative approach seeks to improve the quality of life for millions of patients worldwide suffering from various neurodegenerative conditions.
Hopstem
Series A in 2021
Hopstem Biotechnology LLC is a Houston-based company that focuses on the development of neural stem cell technology and stem cell therapies specifically for neurological disorders. Established in 2019, the company specializes in the neural differentiation, cell banking, and cell engineering of human induced pluripotent stem cells (iPSCs) and human embryonic stem cells (ESCs). By leveraging its advanced technologies, Hopstem aims to enhance biomedical research and improve diagnostic and therapeutic options for various neurological conditions. Through its innovative approaches, the company seeks to provide effective treatment solutions for patients suffering from these disorders.
IntoCare
Series D in 2021
IntoCare is a high-tech company specializing in surgical products such as "Smart" powered staplers.
Synaptic Medical
Series G in 2021
Synaptic Medical Inc. is a medical device company that develops and commercializes products aimed at treating cardiac arrhythmias and other cardiovascular diseases. Founded in 2005, the company operates from its headquarters in St. Paul, Minnesota, and has an additional office in Beijing, China. Synaptic Medical specializes in cardiac electrophysiology products, including bipolar pacing systems, fixed curve and deflectable diagnostic catheters, pulmonary vein mapping catheters, and ablation technologies. The company's mission is to create innovative, cost-effective, and clinically advanced solutions that enhance treatment options for physicians and their patients.
Tavotek Biotherapeutics
Series A in 2021
Tavotek is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Our company management and advisors consist of veteran pharmaceutical executives with multiple prior successes in the development of many blockbuster biologics currently in the market. Tavotek has 3 diverse R&D platform for biologics: TavoSelect (an innovative Phage Display Library), TavoPrecise (engineering platform for tissue-specific biologics), and TavoMIP (a multicyclic peptide platform). Along with these platforms, Tavotek has a rich and diverse pipeline of product candidates in various stages of development, focused on cancers, autoimmune conditions, and infectious diseases.
Pro-Heal
Seed Round in 2021
Pro-Heal Pharmaceuticals is a biotechnology company specializing in the development of pharmaceutical products, particularly for ophthalmic and autoimmune diseases. The company is dedicated to creating biological macromolecule drugs and ophthalmology medicines that address urgent clinical needs, offering innovative solutions for patients who lack access to effective treatments. By focusing on these critical areas, Pro-Heal aims to advance healthcare outcomes and provide essential therapies that are currently unavailable in the market.
Changmugu Medical
Venture Round in 2021
Beijing Changmugu Medical Technology Co., Ltd. is a healthcare startup specializing in artificial intelligence-powered solutions for orthopedic surgery. The company focuses on enhancing the accuracy and safety of surgical procedures through advanced technologies, including AI-assisted diagnosis and individualized operation plans. Additionally, it offers 3D printing patient-specific instrumentation (PSI) for surgical navigation and post-operative intelligent evaluation services. By leveraging AI deep learning, Changmugu Medical aims to provide innovative tools that improve patient outcomes and streamline surgical processes, ultimately contributing to safer and more stable operations in the field of orthopedics.
KYinno
Series A in 2021
KYinno is a drug development company that is dedicated to oncology drug development with a focus on immune treatments against cancer.
HuiKai
Series A in 2021
HuiKai Medical focuses on the research and development, as well as the manufacturing of medical devices tailored for the urinary system. The company's product range addresses various urological conditions, including prostatic hyperplasia, urinary stones, urinary incontinence, and urological tumors. By employing proprietary technology and innovative materials, HuiKai Medical aims to enhance patient comfort and streamline procedures, thereby improving overall healthcare efficiency and outcomes.
PegBio
Private Equity Round in 2020
Founded in 2008 and based in Suzhou, PegBio is a biopharmaceutical company focused on developing innovative treatments for diabetes and obesity. The company's flagship product, PB-119, is a glucagon-like peptide 1 (GLP-1) agonist designed to improve the management of diabetes by allowing patients to take medication once a week, in contrast to the daily injections typically required. PegBio's research extends beyond diabetes, encompassing areas such as nonalcoholic fatty liver disease, gout, cardiovascular conditions, and cancer. The company aims to address significant health challenges through its advanced drug discovery efforts.
OMNI
Series C in 2020
OMNI is an innovative pharmaceutical company focusing on the development of drug delivery technology. OMNI provides inhalation dosage forms, including inhalation aerosol, inhalation powder aerosol, inhalation nebulized solution, and nasal spray, and a design platform for supporting respiratory devices for asthma and chronic obstructive pulmonary disease.
Yingsheng Biology
Series B in 2020
Yingsheng Biotechnology Co., Ltd., established in 2009, specializes in the development and production of in vitro diagnostic reagents and medical equipment focused on maternal and child health, neonatal genetic diseases, and metabolic disorders. The company offers a diverse range of products, including 45 innovative genetic metabolic disease screening reagents, deaf genetic testing kits, and HLA-B27 detection kits. These products aim to facilitate early detection of genetic conditions and birth defects, promoting timely intervention and disease prevention. Yingsheng Bio utilizes advanced molecular diagnostic techniques and sophisticated detection systems, contributing significantly to the fields of human genetics and public health.
GensKey
Series C in 2020
GensKey is a medical diagnostic service provider specializing in genetic testing for pathogen diagnosis. Utilizing high-throughput sequencing technology and intelligent algorithm analysis, GensKey addresses traditional challenges such as low detection rates, lengthy processes, and diagnostic accuracy. This innovative approach allows for timely and precise diagnoses for patients suffering from severe infections, ultimately improving patient outcomes by facilitating quicker access to appropriate medical interventions.
Zylox
Series C in 2020
Zylox Medical Device Co. was established in 2012 in Hangzhou by a team of experienced professionals who returned to China after working in prominent medical device companies in the US and Europe. The company specializes in developing innovative interventional and implantable devices for peripheral and neurovascular applications. Its product portfolio includes a range of devices such as PTA balloons, drug-coated PTA balloons, stents, and thrombectomy devices. Zylox is committed to providing high-quality medical solutions aimed at improving patient care and enhancing the capabilities of healthcare professionals. The company continues to expand its product offerings to address various vascular conditions both in China and internationally.
Delta Medical
Series D in 2020
Demei Medical specializes in the design and manufacture of sports medicine surgical equipment, intraoperative consumables, and rehabilitation products, with a focus on arthroscopic surgery and sports rehabilitation products.
X-ABT
Series B in 2020
X-ABT is a tech enterprise that provides solutions for pathogenic microorganism detection in the medical and health fields. The company focuses on providing complete solutions for the detection of infectious pathogens in the medical and health field. They develop and produce systems for disease control, prevention, clinical hospitals, and entry-exit customs. X-ABT also provides clinical marketing and sales services to help medical workers and serve patients.
IntoCare
Series C in 2020
IntoCare is a high-tech company specializing in surgical products such as "Smart" powered staplers.
AIVFO
Venture Round in 2020
AIVFO produces full-line culture fluids and intelligent automation equipment.
Bioheart
Series B in 2019
Shanghai Baixin'an Biotechnology Co., Ltd. is to develop independent innovative products in the future, continuously develop high-value minimally invasive therapeutic products, provide better medical products and technologies for medical workers and patients, and make the largest medical and health care business. s hard work.
Dami&Xiaomi
Series B in 2019
Shenzhen Dami He Xiaomi Cultural Broadcast Co., Ltd., known as Dami & Xiaomi, operates an online platform dedicated to supporting children with autism spectrum disorders. Established in 2014 and based in Shenzhen, China, the company offers a range of integrated services including rehabilitation, educational support, parent training, online courses, and science information. Dami & Xiaomi aims to address the needs of children with developmental disorders, focusing on effective strategies to help them manage autism and promote healthy growth. Through its comprehensive platform, it provides essential resources to empower parents and caregivers in their efforts to support their children's development.
EOC Pharma Group
Series C in 2019
EOC Pharma is an integrated biopharmaceutical company that is focused on the manufacturing, development and commercialization of innovative global oncology products in China. They have adopted a licensing model in order to build EOC’s innovative pipeline by plugging their partner’s molecule into EOC’s “core engine” of local manufacturing, clinical development, regulatory filing, and commercialization. The company has a pipeline of seven novel products from global biopharmaceutical partners that are potentially first- and best-in-class. Until now, EOC has obtained four Class I innovative drug CTA approvals and initiated clinical studies of four lead products in China.,EOC has a team of entrepreneurs and consultants with overseas background that boasts of first-class pharmaceutical R&D expertise as well as rich industry experience. The company owns an 8,000 square meter cGMP manufacturing facility in Taizhou, China Medical City and has offices in Shanghai, Beijing, Hong Kong and Los Angeles. EOC will leverage forward-looking licensing which will provide product opportunities to their integrated platform, generating a highly strategic portfolio. Ultimately, this will position EOC at the top of oncology innovation in China.
Ruixun Biotech
Series A in 2019
Ruixun Biotech is a healthcare company that provides biotechnology. Ruixun Biotech combines microfluidics, optics, precision instruments, electronic engineering, and biochemical technologies to create upstream equipment and consumables for molecular diagnosis and genetic testing. They released a number of products, including the digital PCR apparatus DropX-2000 and more than 50 different RUO detection kits.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.